Clinical trials: Plasma Cell Tumor
Lymphoma, Leukemia
Phase I Study of Sequential Cord Blood Transplants
The purpose of this study is to determine the safety of sequential cord blood transplantation (2 cord blood units) for patients who have diseases that are capable of being cured by allogeneic stem cell transplant but do not have…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
- Trial name
- NCT00299767
- Testing
- sequential cord blood transplantation
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Malignant Lymphoma, Stem Cell Type, Autologous Transplant
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
The purpose of this study is to determine if the combination of G-CSF and bortezomib is safe and effective in blood cell mobilization.
- Trial name
- NCT01171092
- Testing
- bortezomib and G-CSF
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Kansas Medical Center
Non Small Cell Lung Carcinoma
Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer
A study to determine the concordance of key actionable genomic alterations as assessed in tumor tissue and plasma from patients with non small cell lung carcinoma (NSCLC)
- Trial name
- NCT02762877
- Where
- 22 sites in United States, Chile and 5 more
- Volunteers
- 140 people
- Sponsor
- Genomic Health®, Inc.
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Chronic Lymphocytic Leukemia, Lymphoproliferative Disorders
- Trial name
- NCT03601819
- Testing
- Pacritinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma, Lymphoma, Non-Hodgkin
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
This study will compare the results of stem cell mobilization using drugs called filgrastim (Neupogen) and plerixafor with the results of stem cell mobilization using drugs called XM02 filgrastim (Granix) and plerixafor.
- Trial name
- NCT02098109
- Testing
- XM02 Filgrastim, Filgrastim, Apheresis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Washington University School of Medicine
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
This phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP together with gemcitabine in treating patients with advanced solid tumors or lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma
- Trial name
- NCT00293345
- Testing
- gemcitabine hydrochloride, triapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
This experimental study evaluates the effects of a series of intensive drug regimens as initial treatment for Multiple Myeloma followed by 2 bone marrow transplantations 4-6 months apart in support of high-dose Melphalan…
- Trial name
- NCT00580372
- Testing
- VAD, High-Dose cyclophosphamide, Hemopoietic stem cell procurement
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- University of Arkansas
Colorectal Cancer Stage IV, Colorectal Cancer Metastatic
Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis
Patients with peritoneal metastasis of colorectal or high grade appendiceal origin who are candidates for cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy) will be enrolled in this study.
- Conditions
- Colorectal Cancer Stage IV, Colorectal Cancer Metastatic, Colorectal Cancer, Genetics of, Appendix Cancer
- Trial name
- NCT04157322
- Testing
- prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Chicago
Cancer, Cancer Survivors
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
The goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside in Metro Detroit, Michigan.
- Conditions
- Cancer, Cancer Survivors, Gastrointestinal Cancers, Neuroendocrine Tumors
- Trial name
- NCT06908629
- Testing
- Implementation of social determinants of health screening and referral
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Multiple Myeloma
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter…
- Trial name
- NCT04570631
- Testing
- Eftozanermin alfa, Bortezomib, Dexamethasone
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 4 people
- Sponsor
- AbbVie
Waldenstrom Macroglobulinemia, MYD88 Gene Mutation
Ibrutinib + Venetoclax in Untreated WM
This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation.
- Trial name
- NCT04273139
- Testing
- IBRUTINIB, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer, Adenoma
A Multi-center Trial to Establish a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA
In this study, the investigators establish a model for the early diagnosis of colorectal cancer based on the detection of 5-hydroxymethylcytosine (5-hmC) in training group and validate the effectiveness of the model using a…
- Trial name
- NCT03676075
- Where
- China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Fudan University
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial is studying the side effects and best dose of obatoclax when given together with bortezomib and to see how well they work in treating patients with relapsed or refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00719901
- Testing
- obatoclax mesylate, bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
The hypothesis for this study is that the regimen consisting of fludarabine, melphalan and bortezomib improves the progression free survival and the response rate compared to historical controls of fludarabine and melphalan alone.
- Trial name
- Flu-Mel-Vel (NCT01453101)
- Testing
- Fludarabine monophosphate, melphalan, Bortezomib
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Hackensack Meridian Health
Multiple Myeloma
UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies
The researchers want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.
- Trial name
- NCT00578045
- Testing
- Transfusion
- Where
- United States
- Sponsor
- University of Arkansas
Acyanotic Congenital Heart Disease, Cyanotic Congenital Heart Disease
Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease
The aim of our study is to compare plasma metanephrines in patients with cyanotic and acyanotic congenital heart disease and possible association with chronic hypoxic stress.
- Conditions
- Acyanotic Congenital Heart Disease, Cyanotic Congenital Heart Disease, Pheochromocytoma, Paraganglioma
- Trial name
- NCT04891081
- Where
- Slovenia
- Volunteers
- 50 people
- Sponsor
- University Medical Centre Ljubljana
Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Signification
Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy
Blood circulating endothelial cells (CEC) and microparticles (MPs) are described in the literature to be associated with vascular failures and dysfunction that reflect neo-angiogenesis and risk of thrombosis, respectively.
- Conditions
- Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Signification, Myeloma
- Trial name
- PACMoG (NCT01543100)
- Testing
- blood and bone marrow samples
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Rennes University Hospital
Refractory Multiple Myeloma
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
Phase 2, single-arm, open, non-randomized, multicenter study of the SINE™ compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab.
- Trial name
- NCT03589222
- Testing
- Selinexor, Daratumumab, Bortezomib
- Where
- 15 sites in Spain
- Volunteers
- 62 people
- Sponsor
- PETHEMA Foundation
Light-Chain Amyloidosis
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated…
- Trial name
- NCT01318902
- Testing
- Ixazomib, Dexamethasone
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma
The study involves the use of a targeted form of radiation, in addition to standard high dose chemotherapy and stem cell transplant for multiple myeloma.
- Trial name
- NCT01207765
- Testing
- indium-111-ibritumomab tiuxetan, 90Y Zevalin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Tufts Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.